Catalyst Event
AbbVie Inc (ABBV) · Other
From KEDI U.S. Medical AI Index (KUSMAI)
4/24/2026, 12:00:00 AM
On April 24, 2026, AbbVie received a Complete Response Letter (CRL) from the FDA for its experimental wrinkle treatment, trenibotulinumtoxinE, due to manufacturing-related issues, delaying its potential market entry.
Korean Translation
2026년 4월 24일, AbbVie는 제조 관련 문제로 인해 실험적인 주름 치료제 트레니보툴리눔톡신E에 대해 FDA로부터 최종 보완 요구 서신(CRL)을 받아 잠재적인 시장 출시가 지연됨.
Related Recent Events
NVIDIA Corporation (NVDA) · Earnings Release
NVIDIA's Q1 fiscal 2027 earnings release is scheduled for May 20, 2026. Low importance assigned as the announcement of an earnings date typically results in ~1% price impact, scheduled.
5/20/2026, 12:00:00 AM
Hims & Hers Health Inc (HIMS) · Earnings Release
First quarter 2026 financial results and conference call on May 11, 2026, with high importance estimated due to potential market impact of earnings guidance, scheduled.
5/11/2026, 12:00:00 AM
Caris Life Sciences Inc (CAI) · Earnings Release
First quarter 2026 financial results on May 7, 2026, to be released after market close; significant price impact expected based on recent growth trends scheduled.
5/7/2026, 12:00:00 AM
Natera Inc (NTRA) · Earnings Release
Natera is expected to announce its Q1 2026 financial results scheduled. Scheduled earnings releases are key volatility events with an estimated 5% impact.
5/7/2026, 12:00:00 AM
Tempus AI Inc (TEM) · Earnings Release
First quarter 2026 financial results and business update scheduled for May 5, 2026; high impact from potential 10% price volatility expected.
5/5/2026, 12:00:00 AM
BioNTech SE (BNTX) · Earnings Release
BioNTech will report first-quarter 2026 financial results and provide a corporate update on 2026-05-05; given the sharp March 2026 volatility after guidance and leadership news, this update is likely to be closely watched and could move shares materially, expected.
5/5/2026, 12:00:00 AM